Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Renu, Eapen"'
Autor:
Muhammad Ali, Kendrick Koo, David Chang, Phil Chan, Sheng F. Oon, Daniel Moon, Declan G. Murphy, Renu Eapen, Jeremy Goad, Nathan Lawrentschuk, Arun A. Azad, Sarat Chander, Mark Shaw, Nicholas Hardcastle, Shankar Siva
Publikováno v:
Radiation Oncology, Vol 19, Iss 1, Pp 1-9 (2024)
Abstract Background Stereotactic ablative body radiotherapy (SABR) is an emerging treatment for patients with primary renal cell carcinoma (RCC). However, its impact on renal function is unclear. This study aimed to evaluate incidence and clinical fa
Externí odkaz:
https://doaj.org/article/08cdee63f1d54833baeea559c883b2c1
Autor:
Cristian Udovicich, Jason Callahan, Mathias Bressel, Wee Loon Ong, Marlon Perera, Ben Tran, Arun Azad, Shankar Haran, Daniel Moon, Sarat Chander, Mark Shaw, Renu Eapen, Jeremy Goad, Nathan Lawrentschuk, Declan G. Murphy, Michael Hofman, Shankar Siva
Publikováno v:
European Urology Open Science, Vol 44, Iss , Pp 60-68 (2022)
Background: Prostate-specific membrane antigen (PSMA) is overexpressed in the neovasculature of renal cell carcinoma (RCC). However, there remains limited evidence regarding the use of PSMA positron emission tomography/computed tomography (PET/CT) in
Externí odkaz:
https://doaj.org/article/66976b2987cf4402b5e63b4c52c38980
Autor:
Muhammad Ali, Simon Wood, David Pryor, Daniel Moon, Mathias Bressel, Arun A. Azad, Catherine Mitchell, Declan Murphy, Homi Zargar, Nick Hardcastle, Jamie Kearsley, Renu Eapen, Lih Ming Wong, Katharine Cuff, Nathan Lawrentschuk, Paul J. Neeson, Shankar Siva
Publikováno v:
Contemporary Clinical Trials Communications, Vol 33, Iss , Pp 101145- (2023)
Background: Surgery remains the standard of care for localised renal cell carcinoma (RCC). Nevertheless, nearly 50% of patients with high-risk disease experience relapse after surgery, with distant sites being common. Considering improved outcomes in
Externí odkaz:
https://doaj.org/article/4d0e507036ae41018c85cc8e525fcedc
Publikováno v:
Société Internationale d’Urologie Journal, Vol 1, Iss 1, Pp 30-38 (2020)
At every stage of the prostate cancer journey from screening and diagnosis to management of advanced disease, patients and clinicians face dilemmas and decisions that can impact long-term outcomes. Although traditional risk stratification in prostate
Externí odkaz:
https://doaj.org/article/acad4680d3f446459fc7320f4344a291
Publikováno v:
Société Internationale d’Urologie Journal, Vol 1, Iss 1, Pp 23-29 (2020)
The clinical course of localized prostate cancer varies widely, from indolent disease unlikely to need treatment to aggressive disease requiring intensive, multimodal therapy. Traditionally, treatment decisions have been based on clinical and patholo
Externí odkaz:
https://doaj.org/article/89fb3411936b4704ad5ee2857116dddd
Publikováno v:
European Urology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bcde29de356bec34bdb09fd8acd1b447
https://doi.org/10.1016/j.eururo.2023.05.001
https://doi.org/10.1016/j.eururo.2023.05.001
Autor:
Nathan Lawrentschuk, Omar Alghazo, Renu Eapen, Rebecca Loh, Declan G. Murphy, Marcus G. Cumberbatch, Samantha Koschel, James Buteau
Publikováno v:
Future Oncology. 17:3637-3644
Despite the remarkable achievements in treating metastatic prostate cancer over the last two decades, castrate-resistant status is still considered the lethal stage of the disease. Theranostics combines a targeting compound (ligand) with a therapeuti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc119a1a1a4954b5719e7c0471c08994
https://doi.org/10.2217/fon-2020-1209
https://doi.org/10.2217/fon-2020-1209
Autor:
Jeremy Yuen-Chun Teoh, Peter C. Black, Carmen Mir, Tian Zhang, Simon Tanguay, Kilian M. Gust, Sima P. Porten, Angela B. Smith, Tilman Todenhöfer, Renu Eapen, Ashish M. Kamat, Srikala S. Sridhar
Publikováno v:
Proceedings from the SIU B2B Uro-Oncology: GU Cancers Triad Virtual Meeting May 21–22, 2021. 2:S7-S16
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7f983eebac30ad51ba9bda2413795111
https://doi.org/10.48083/njcd1236
https://doi.org/10.48083/njcd1236
Autor:
Shahneen Sandhu, Simon P. Keam, Scott Williams, Catherine Mitchell, Michael S Hofman, Paul J Neeson, Renu Eapen, Nathan Lawrentschuk, Price Jackson, Omar Alghazo, Arun Azad, Declan G. Murphy, Mark Scalzo, Nattakorn Dhiantravan, Daniel Moon, John Violet
Publikováno v:
European Urology Focus. 7:234-237
LuTectomy is an open-label phase 1/2 nonrandomised clinical trial evaluating the dosimetry, efficacy, and toxicity of the lutetium-177-radiolabelled small molecule PSMA-617 in men with high-risk localised/locoregional advanced prostate cancer with hi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e2eb9dfb8957c5b12d80fb6205f4b93
https://doi.org/10.1016/j.euf.2020.09.021
https://doi.org/10.1016/j.euf.2020.09.021
Autor:
Jonathan S. O’Brien, Aoife McVey, Brian D. Kelly, Pocharapong Jenjitranant, James Buteau, Michael S. Hofman, Veeru Kasivisvanithan, Renu Eapen, Daniel Moon, Declan G. Murphy, Nathan Lawrentschuk
Publikováno v:
BJU internationalReferences. 130
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d5d88594129de3519f48a52eb7913c0
https://pubmed.ncbi.nlm.nih.gov/35574991
https://pubmed.ncbi.nlm.nih.gov/35574991